NRX Pharmaceuticals, Inc. (NRXP)

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Free Report) - Research analysts at HC Wainwright issued their Q1 2027 earnings estimates for NRx Pharmaceuticals in a note issued to investors on Monday, April 27th. HC Wainwright analyst P. Trucchio expects that the company will post earnings per share of $

NRx Pharmaceuticals (NASDAQ:NRXP) said it advanced several regulatory, manufacturing and clinical initiatives during the first quarter of 2026, including progress toward potential approval of its preservative-free ketamine product, KETAFREE, and preparations for an NDA filing for NRX-100. Founder,

Get real-time NRX Pharmaceuticals Inc (NRXP) stock price, news, financials, community insights, and trading ideas. Join 10 million+ investors and traders tracking markets in real-time on Stocktwits.

NRx Pharmaceuticals (NRXP) delivered earnings and revenue surprises of +20.00% and -91.28%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Additional Funding: $7 million raised post-quarter through sale of common stock. Warning! GuruFocus has detected 3 Warning Signs with NRXP. Is NRXP fairly valued? Test your thesis with our free DCF calculator. ... For the complete transcript of the earnings call, please refer to the full earnings ..…